Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies
Open Access
- 25 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (17) , e1897-e1904
Abstract
Background and Objectives Anti–calcitonin gene-related peptide (CGRP) (receptor) antibodies are approved as preventive treatment for migraine. Recent concerns have been raised after a retrospective analysis of postmarketing case reports of elevated blood pressure (BP) associated with erenumab. In this prospective follow-up study, we aimed to assess the safety regarding BP in a real-world setting. Methods All people with migraine who were treated with erenumab and fremanezumab at the Leiden Headache Center between January 2019 and January 2021 were included. BP measurements were collected from baseline (T0) until 12 months of follow-up, with a 3-month interval (T1–T4). Mixed linear models were fitted with time as a fixed effect and the patient as a random effect. Results Both systolic and diastolic BP were increased at all time points T1–T4 compared with T0 (p < 0.001). The maximum estimated increase in the mean systolic BP was 5.2 mm Hg (95% CI 3.1–7.5). The maximum estimated increase in the mean diastolic BP was 3.5 mm Hg (95% CI 2.0–4.9). In the erenumab group (n = 109), both systolic and diastolic BP were increased at all time points compared with T0 (all p < 0.001). For fremanezumab (n = 87), systolic but not diastolic BP was increased compared with T0 at T1 (p = 0.006) and T2 (p = 0.004). Four patients (3.7%) with normal BP at T0 required antihypertensive treatment after erenumab was started. Discussion The mean systolic and diastolic BP increased after anti-CGRP (receptor) antibodies were started. The majority of patients remained within the normal BP limits, but some patients required antihypertensive treatment. Physicians should be aware that people with migraine may be at risk of developing hypertension when treated with anti-CGRP (receptor) antibodies, and this should be added to (inter)national treatment guidelines. Classification of Evidence This study provides Class III evidence that anti-CGRP (receptor) antibodies increase BP when used to treat patients with migraine.Keywords
This publication has 26 references indexed in Scilit:
- Calcitonin gene-related peptide (CGRP) in autonomic cardiovascular regulation and vascular structureJournal of the American Society of Hypertension, 2014
- An Ongoing Role of α-Calcitonin Gene–Related Peptide as Part of a Protective Network Against Hypertension, Vascular Hypertrophy, and Oxidative StressHypertension, 2014
- Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRPCephalalgia, 2014
- White-Coat HypertensionHypertension, 2013
- Migraine Headache and Ischemic Stroke Risk: An Updated Meta-analysisThe American Journal of Medicine, 2010
- Hypertension as a risk factor for migraine chronificationNeurological Sciences, 2010
- Migraine and cardiovascular diseaseNeurology, 2010
- Migraine and cardiovascular disease: systematic review and meta-analysisBMJ, 2009
- Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: The population-based MRI CAMERA studyCephalalgia, 2009
- Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesThe Lancet, 2002